- EU and MENA markets require fundamentally different levels of clinical substantiation for health claims
- EFSA-approved health claims provide the strongest commercial protection in European markets
- In MENA, national health authorities increasingly demand clinical dossiers aligned with WHO guidelines
- Building a clinical evidence strategy early in development reduces time-to-market by up to 40%
The nutraceutical sector sits at the intersection of food science, pharmaceutical standards, and commercial ambition. As regulators across Europe and the MENA region tighten their requirements for health claim substantiation, companies that fail to build credible clinical evidence risk both regulatory rejection and commercial underperformance.
Under EU Regulation 1924/2006, all nutrition and health claims must be scientifically substantiated to the satisfaction of the European Food Safety Authority (EFSA). General function claims (Article 13) require robust human intervention data demonstrating a cause-and-effect relationship between a nutrient and a health outcome. Reduction of disease risk claims (Article 14) demand an even higher evidentiary standard - comparable to pharmaceutical-grade clinical trials.
For nutraceutical companies, this means that the clinical development strategy must be designed with the end regulatory destination in mind. A poorly designed pilot study conducted in 30 subjects will not satisfy EFSA reviewers - and the cost of repeating the work after rejection can exceed €500,000 per product.
Saudi Arabia (SFDA), the UAE (MOHAP), and Morocco (ONSSA) have each developed distinct frameworks for nutraceutical and food supplement registration. While MENA authorities have historically been more flexible than EFSA on claim substantiation, this is rapidly changing. The SFDA now routinely requests clinical summaries, stability data, and ingredient safety justifications for novel actives - particularly botanical extracts, omega-3 concentrates, and peptide-based formulations.
The most efficient approach is to design a single core clinical program that satisfies both EU and MENA requirements. This means: (1) selecting trial designs that generate both efficacy and safety data, (2) including biomarker endpoints validated by both EFSA and regional health authorities, and (3) producing a modular clinical dossier adaptable to each market's submission format.
At SCPS Experts, we guide clients from clinical study design through data interpretation and dossier assembly - ensuring that each investment in clinical evidence generates maximum regulatory and commercial value.